10-Q: Instil Bio Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Instil Bio, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting a net loss of $14.9 million and providing updates on its strategic reprioritization and recent licensing agreement.

Summary

• Instil Bio, Inc. reported a net loss of $14.9 million for the second quarter of 2024 and $39.2 million for the six months ended June 30, 2024.
• As of June 30, 2024, the company had $152.6 million in cash, cash equivalents, marketable securities, and long-term investments.
• The company is focusing on developing a pipeline of novel therapies and has recently in-licensed certain bispecific antibodies from ImmuneOnco Biopharmaceuticals.
• In December 2023, Instil Bio entered into an agreement to develop an autologous FR CoStAR TIL for a potential investigator-initiated trial in non-small cell lung cancer in China.
• The company has implemented strategic reprioritization plans, including the closure of its UK manufacturing facility and cessation of the ITIL-306 clinical trial.
• In July 2024, Instil Bio leased its Tarzana, California manufacturing facility to AstraZeneca Pharmaceuticals LP for an initial term of approximately 15 years, with an initial base rent of $627,276 per month.

Sentiment

Score: 4

Explanation: The document reflects a challenging financial situation with ongoing losses and restructuring. However, the strategic partnerships and asset monetization efforts provide some positive signals. Overall, the sentiment is cautious due to the early stage of development and financial challenges.

Positives

• Instil Bio has secured a significant licensing agreement with ImmuneOnco, expanding its pipeline with promising bispecific antibody candidates.
• The collaboration to develop CoStAR-TIL in China represents a strategic move to tap into the Chinese market and advance its TIL therapy platform.
• The lease agreement with AstraZeneca for the Tarzana facility provides a steady revenue stream and validates the value of the company
• s manufacturing infrastructure.', 'The company maintains a strong cash position, providing financial flexibility to pursue its strategic objectives.'

Negatives

• Instil Bio reported a net loss of $14.9 million for Q2 2024 and $39.2 million for the six months ended June 30, 2024.
• The company has incurred significant operating losses since its inception, with an accumulated deficit of $620.2 million as of June 30, 2024.
• Research and development expenses decreased due to reduced headcount and discontinuation of clinical manufacturing activities for ITIL-168.
• Restructuring and impairment charges of $4.8 million were recorded for the six months ended June 30, 2024, related to the closure of the UK facility and cessation of the ITIL-306 trial.

Risks

• Instil Bio has incurred significant losses since inception and expects continued losses, potentially never achieving profitability.
• The company has a limited operating history and no history of completing clinical trials or commercializing products.
• Substantial additional funding is needed, and failure to raise capital could force delays or curtailment of operations.
• All product candidates are in early-stage development with a high risk of failure.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Difficulties in manufacturing biologics, including potential delays and reliance on third-party manufacturers, could harm the business.
• The company may be unable to obtain or protect intellectual property rights related to its product candidates.
• The company is subject to stringent and evolving data privacy and security regulations.
• The company may be subject to product liability lawsuits.
• The company may be unable to retain key executives or attract and retain qualified personnel.

Future Outlook

Instil Bio expects its existing cash, cash equivalents, restricted cash, and marketable securities to fund operating expenses and capital expenditure requirements beyond 2026. The company is evaluating opportunities for a potential sale of its Tarzana manufacturing site and subleases of other facilities, which could extend its cash runway if successful.

Industry Context

Instil Bios recent in-licensing of bispecific antibodies and focus on TIL cell therapy development aligns with the broader industry trend towards innovative immunotherapies for cancer treatment. The collaboration in China for CoStAR-TIL development reflects the growing importance of the Chinese market in the global biopharmaceutical landscape. The lease agreement with AstraZeneca for the Tarzana facility indicates a strategic shift towards leveraging assets and potentially monetizing infrastructure.

Comparison to Industry Standards

• Instil Bio
• s net loss for Q2 2024 is significant but not uncommon for clinical-stage biopharmaceutical companies, which typically incur substantial R&D expenses before achieving profitability. For example, Iovance Biotherapeutics, Inc. (IOVA), another company focused on TIL therapy, reported a net loss of $107.1 million for Q1 2024.', 'Instil Bio's cash position of $152.6 million provides a reasonable runway, but is lower compared to some peers. For instance, Iovance Biotherapeutics, Inc. (IOVA) reported cash, cash equivalents, and short-term investments of $274.7 million as of March 31, 2024.', 'The lease agreement with AstraZeneca for the Tarzana facility is a positive development, providing a recurring revenue stream. This is comparable to other biopharma companies that have monetized their manufacturing assets through similar arrangements. For example, in 2023, Novartis sold its biologics manufacturing facility in Vacaville, California, to a contract manufacturer for $110 million.', 'Instil Bio's collaboration with ImmuneOnco for the development of bispecific antibodies is in line with industry trends, as many companies are pursuing strategic partnerships to expand their pipelines and access new technologies. For example, in 2023, Amgen acquired Horizon Therapeutics for $27.8 billion, gaining access to a portfolio of rare disease drugs and a pipeline of immunology candidates.'

Stakeholder Impact

• Shareholders may be impacted by the ongoing losses and the need for potential future funding, which could lead to dilution.
• Employees have been affected by the workforce reductions as part of the restructuring plans.
• The collaboration with ImmuneOnco and the lease agreement with AstraZeneca could create new opportunities for employees and suppliers.
• Patients may benefit from the development of new therapies, but the early-stage nature of the programs means that any potential impact is uncertain and long-term.

Next Steps

• Instil Bio will continue to advance the development of the in-licensed bispecific antibodies from ImmuneOnco, including SYN-2510 and SYN-27M.
• The company will work with its collaborator in China to progress the development of the CoStAR-TIL Collaboration Product for the potential investigator-initiated trial in non-small cell lung cancer.
• Instil Bio will seek to complete the sale of its Tarzana manufacturing facility and explore sublease opportunities for other facilities.
• The company will continue to evaluate potential business development activities to expand its pipeline and capabilities.

Key Dates

Keywords

bispecific antibodies, immunotherapy, oncology, PD-L1, VEGF, CTLA-4, SYN-2510, SYN-27M, clinical trials, biopharmaceutical, licensing agreement, tumor infiltrating lymphocyte, TIL cell therapy, CoStAR-TIL, non-small cell lung cancer, NSCLC, China, strategic reprioritization, manufacturing facility, lease agreement, research and development